P Hoever

Summary

Affiliation: Actelion Pharmaceuticals Ltd
Country: Switzerland

Publications

  1. ncbi Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant
    P Hoever
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 87:593-600. 2010

Collaborators

Detail Information

Publications1

  1. ncbi Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant
    P Hoever
    Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    Clin Pharmacol Ther 87:593-600. 2010
    ..Population pharmacokinetic/pharmacodynamic modeling suggested that doses of ~500 mg almorexant and 10 mg zolpidem are equivalent with respect to subjectively assessed alertness...